Abivax SA ABVX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Abivax to Present Three Abstracts for Obefazimod in Ulcerative Colitis at the UEG Week 2024
-
Abivax Provides Update on Ulcerative Colitis (UC) Combination Therapy Program Strategy and Announces Early Preclinical Combination Data of Obefazimod and Etrasimod in Inflammatory Bowel Disease (IBD) Mouse Model
-
Abivax presents first-half 2024 financial results
-
Abivax Announces ABTECT Phase 3 Trial Achieves Key Enrollment Milestone
-
Abivax Provides Operational and Key Program Update
-
Abivax increases size of Nasdaq uplisting deal
Trading Information
- Previous Close Price
- €10.24
- Day Range
- €10.16–10.40
- 52-Week Range
- €7.89–15.42
- Bid/Ask
- €10.04 / €10.48
- Market Cap
- €640.50 Mil
- Volume/Avg
- 5,706 / 17,737
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. They are evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two most common forms are UC and CD.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 61
- Website
- https://www.abivax.com
Comparables
Valuation
|
Metric
|
ABVX
|
BHVN
|
EXEL
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | 17.02 |
Price/Book Value | 3.27 | 12.27 | 3.49 |
Price/Sales | — | — | 3.97 |
Price/Cash Flow | — | — | 16.25 |
Price/Earnings
ABVX
BHVN
EXEL
Financial Strength
|
Metric
|
ABVX
|
BHVN
|
EXEL
|
|---|---|---|---|
Quick Ratio | 4.00 | 2.85 | 4.05 |
Current Ratio | 4.08 | 3.27 | 4.27 |
Interest Coverage | −9.89 | — | — |
Quick Ratio
ABVX
BHVN
EXEL
Profitability
|
Metric
|
ABVX
|
BHVN
|
EXEL
|
|---|---|---|---|
Return on Assets (Normalized) | −70.24% | −141.24% | 14.82% |
Return on Equity (Normalized) | −142.04% | −189.64% | 19.05% |
Return on Invested Capital (Normalized) | −89.54% | −174.81% | 14.99% |
Return on Assets
ABVX
BHVN
EXEL
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk AS ADR
NVO
| Lprbfqwgn | Kypwq | $531.4 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Kmnhrxsx | Blfdrb | $119.5 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Xqjnkdxzq | Hhvlnc | $114.9 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Qmqjrrfm | Htyccbd | $35.3 Bil | |||
| argenx SE ADR
ARGX
| Gdqzpyhh | Rvdk | $32.0 Bil | |||
| BioNTech SE ADR
BNTX
| Mjhzhjfc | Cmjtf | $28.1 Bil | |||
| Moderna Inc
MRNA
| Tztfvgnq | Pjb | $25.3 Bil | |||
| United Therapeutics Corp
UTHR
| Ggtwzrm | Qmdqn | $16.0 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Bngdhbny | Gvrkm | $13.4 Bil | |||
| Incyte Corp
INCY
| Drcglks | Kfncqhp | $12.7 Bil |
United States